Monitoring/Imaging and Regenerative Agents for Enhancing Tissue Engineering Characterization and Therapies

• Type of Material: Article
• Authors: Daniela Y. Santiesteban, University of Texas Austin; Kelsey Kubelick, Georgia Institute of Technology; Kabir S. Dhada, University of Texas Austin; Diego Dumani, Georgia Institute of Technology; Laura Suggs, University of Texas Austin; Stanislav Emelianov, Emory University
• Language: English
• Date: 2016-03-01
• Publisher: Springer Verlag (Germany)
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2015, Biomedical Engineering Society.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1007/s10439-015-1509-y
• Title of Journal or Parent Work: Annals of Biomedical Engineering
• ISSN: 0090-6964
• Volume: 44
• Issue: 3
• Start Page: 750
• End Page: 772
• Keywords: Engineering; Multimodal tracking; IN-VIVO TRANSFECTION; IRON-OXIDE NANOPARTICLES; LONG-TERM FATE; Engineering, Biomedical; Therapeutic agents; Regenerative medicine; Imaging contrast agents; MESENCHYMAL STEM-CELLS; ACOUSTIC RADIATION FORCE; DRUG-DELIVERY; Science & Technology; COATED GOLD NANOPARTICLES; Real-time imaging; Scaffold engineering; ULTRASOUND CONTRAST AGENTS; WALLED CARBON NANOTUBES; In vivo imaging; Stem cells; In vivo tracking; MESOPOROUS SILICA NANOPARTICLES; Technology
• Research Categories: Engineering, Biomedical; Health Sciences, Rehabilitation and Therapy

Abstract

The past three decades have seen numerous advances in tissue engineering and regenerative medicine (TERM) therapies. However, despite the successes there is still much to be done before TERM therapies become commonplace in clinic. One of the main obstacles is the lack of knowledge regarding complex tissue engineering processes. Imaging strategies, in conjunction with exogenous contrast agents, can aid in this endeavor by assessing in vivo therapeutic progress. The ability to uncover real-time treatment progress will help shed light on the complex tissue engineering processes and lead to development of improved, adaptive treatments. More importantly, the utilized exogenous contrast agents can double as therapeutic agents. Proper use of these Monitoring/Imaging and Regenerative Agents (MIRAs) can help increase TERM therapy successes and allow for clinical translation. While other fields have exploited similar particles for combining diagnostics and therapy, MIRA research is still in its beginning stages with much of the current research being focused on imaging or therapeutic applications, separately. Advancing MIRA research will have numerous impacts on achieving clinical translations of TERM therapies. Therefore, it is our goal to highlight current MIRA progress and suggest future research that can lead to effective TERM treatments.